Mitigation of opioid off-target effects and identification of structural drivers of opioid receptor engagement for BACE-1 small molecule inhibitors

Dolores Diaz, Donna Dambach, Michael Siu, Kevin Hunt, Allen Thomas, Joseph Lyssikatos, Xingrong Liu, Sock Lewin-Koh, Bobby Mccray, Kevin Ford

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Application of safety lead optimization screening strategies during the early stage of drug discovery led to the identification of a series of CNS-active small molecule inhibitors with opioid off-target effects, as evidenced by potent agonistic activity in functional cell-based assays for mu (MOP), kappa (KOP) and delta (DOP) opioid receptors. The translation of these effects was confirmed in vivo with the following observations: hypoactivity and decreased fecal production in rats (characteristic of MOP agonism); increased urine production in rats (characteristic of KOP agonism); and decreased intestinal transit time in mice, which was partially blocked by the MOP antagonist naloxone, demonstrating that the in vivo effects were specific for MOP. Based on the confirmation of in vitro-in vivo translatability, an in vitro screening strategy was implemented that resulted in the identification of an optimized backup molecule, devoid of in vivo off-target opioid effects. In addition, in silico modeling by docking of the various molecules to the opioid receptors allowed the identification of the structural drivers of these off-target effects, which can be applied to future chemical-design criteria.Thus, implementation of the safety lead optimization strategy described in this article demonstrates the utility and impact of such approaches on risk mitigation and identification of lead small molecules with improved safety profiles.

Original languageEnglish (US)
Pages (from-to)478-486
Number of pages9
JournalToxicology Mechanisms and Methods
Volume25
Issue number6
DOIs
StatePublished - Jul 24 2015

Fingerprint

Opioid Receptors
Opioid Analgesics
Safety
Molecules
Rats
Screening
delta Opioid Receptor
Drug Discovery
Naloxone
Computer Simulation
Urine
Assays
In Vitro Techniques

Keywords

  • BACE-1
  • charcoal transit
  • lead optimization
  • modeling
  • opioid

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Mitigation of opioid off-target effects and identification of structural drivers of opioid receptor engagement for BACE-1 small molecule inhibitors. / Diaz, Dolores; Dambach, Donna; Siu, Michael; Hunt, Kevin; Thomas, Allen; Lyssikatos, Joseph; Liu, Xingrong; Lewin-Koh, Sock; Mccray, Bobby; Ford, Kevin.

In: Toxicology Mechanisms and Methods, Vol. 25, No. 6, 24.07.2015, p. 478-486.

Research output: Contribution to journalArticle

Diaz, Dolores ; Dambach, Donna ; Siu, Michael ; Hunt, Kevin ; Thomas, Allen ; Lyssikatos, Joseph ; Liu, Xingrong ; Lewin-Koh, Sock ; Mccray, Bobby ; Ford, Kevin. / Mitigation of opioid off-target effects and identification of structural drivers of opioid receptor engagement for BACE-1 small molecule inhibitors. In: Toxicology Mechanisms and Methods. 2015 ; Vol. 25, No. 6. pp. 478-486.
@article{a2db84ffee98420fb0d78770258411ea,
title = "Mitigation of opioid off-target effects and identification of structural drivers of opioid receptor engagement for BACE-1 small molecule inhibitors",
abstract = "Application of safety lead optimization screening strategies during the early stage of drug discovery led to the identification of a series of CNS-active small molecule inhibitors with opioid off-target effects, as evidenced by potent agonistic activity in functional cell-based assays for mu (MOP), kappa (KOP) and delta (DOP) opioid receptors. The translation of these effects was confirmed in vivo with the following observations: hypoactivity and decreased fecal production in rats (characteristic of MOP agonism); increased urine production in rats (characteristic of KOP agonism); and decreased intestinal transit time in mice, which was partially blocked by the MOP antagonist naloxone, demonstrating that the in vivo effects were specific for MOP. Based on the confirmation of in vitro-in vivo translatability, an in vitro screening strategy was implemented that resulted in the identification of an optimized backup molecule, devoid of in vivo off-target opioid effects. In addition, in silico modeling by docking of the various molecules to the opioid receptors allowed the identification of the structural drivers of these off-target effects, which can be applied to future chemical-design criteria.Thus, implementation of the safety lead optimization strategy described in this article demonstrates the utility and impact of such approaches on risk mitigation and identification of lead small molecules with improved safety profiles.",
keywords = "BACE-1, charcoal transit, lead optimization, modeling, opioid",
author = "Dolores Diaz and Donna Dambach and Michael Siu and Kevin Hunt and Allen Thomas and Joseph Lyssikatos and Xingrong Liu and Sock Lewin-Koh and Bobby Mccray and Kevin Ford",
year = "2015",
month = "7",
day = "24",
doi = "10.3109/15376516.2015.1070228",
language = "English (US)",
volume = "25",
pages = "478--486",
journal = "Toxicology Mechanisms and Methods",
issn = "1537-6516",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mitigation of opioid off-target effects and identification of structural drivers of opioid receptor engagement for BACE-1 small molecule inhibitors

AU - Diaz, Dolores

AU - Dambach, Donna

AU - Siu, Michael

AU - Hunt, Kevin

AU - Thomas, Allen

AU - Lyssikatos, Joseph

AU - Liu, Xingrong

AU - Lewin-Koh, Sock

AU - Mccray, Bobby

AU - Ford, Kevin

PY - 2015/7/24

Y1 - 2015/7/24

N2 - Application of safety lead optimization screening strategies during the early stage of drug discovery led to the identification of a series of CNS-active small molecule inhibitors with opioid off-target effects, as evidenced by potent agonistic activity in functional cell-based assays for mu (MOP), kappa (KOP) and delta (DOP) opioid receptors. The translation of these effects was confirmed in vivo with the following observations: hypoactivity and decreased fecal production in rats (characteristic of MOP agonism); increased urine production in rats (characteristic of KOP agonism); and decreased intestinal transit time in mice, which was partially blocked by the MOP antagonist naloxone, demonstrating that the in vivo effects were specific for MOP. Based on the confirmation of in vitro-in vivo translatability, an in vitro screening strategy was implemented that resulted in the identification of an optimized backup molecule, devoid of in vivo off-target opioid effects. In addition, in silico modeling by docking of the various molecules to the opioid receptors allowed the identification of the structural drivers of these off-target effects, which can be applied to future chemical-design criteria.Thus, implementation of the safety lead optimization strategy described in this article demonstrates the utility and impact of such approaches on risk mitigation and identification of lead small molecules with improved safety profiles.

AB - Application of safety lead optimization screening strategies during the early stage of drug discovery led to the identification of a series of CNS-active small molecule inhibitors with opioid off-target effects, as evidenced by potent agonistic activity in functional cell-based assays for mu (MOP), kappa (KOP) and delta (DOP) opioid receptors. The translation of these effects was confirmed in vivo with the following observations: hypoactivity and decreased fecal production in rats (characteristic of MOP agonism); increased urine production in rats (characteristic of KOP agonism); and decreased intestinal transit time in mice, which was partially blocked by the MOP antagonist naloxone, demonstrating that the in vivo effects were specific for MOP. Based on the confirmation of in vitro-in vivo translatability, an in vitro screening strategy was implemented that resulted in the identification of an optimized backup molecule, devoid of in vivo off-target opioid effects. In addition, in silico modeling by docking of the various molecules to the opioid receptors allowed the identification of the structural drivers of these off-target effects, which can be applied to future chemical-design criteria.Thus, implementation of the safety lead optimization strategy described in this article demonstrates the utility and impact of such approaches on risk mitigation and identification of lead small molecules with improved safety profiles.

KW - BACE-1

KW - charcoal transit

KW - lead optimization

KW - modeling

KW - opioid

UR - http://www.scopus.com/inward/record.url?scp=84942506103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942506103&partnerID=8YFLogxK

U2 - 10.3109/15376516.2015.1070228

DO - 10.3109/15376516.2015.1070228

M3 - Article

C2 - 26275124

AN - SCOPUS:84942506103

VL - 25

SP - 478

EP - 486

JO - Toxicology Mechanisms and Methods

JF - Toxicology Mechanisms and Methods

SN - 1537-6516

IS - 6

ER -